What is the context of your innovation?
The context of our innovation is skin care, aimed at consumers, cosmetics operators and dermatologists. SKID, using autofluorescence and AI, offers a rapid, economical and non-invasive solution to personalize treatments and diagnose pathologies early.

What is your project about?
SKID, uses skin autofluorescence and artificial intelligence to quickly and economically determine skin biotype. This solves the problem of the complexity and high cost of traditional methods. SKID uses a specific light source to analyze the skin, improving accessibility and precision.

What are the next steps?
SKID is in the experimental phase, with promising preliminary results in the detection of skin biotypes via autofluorescence. We are refining the AI ​​algorithm and conducting further tests to validate the system. We have plans for future deployments and collaborations to improve and deploy the technology.